Please login to the form below

Not currently logged in
Email:
Password:

US and Canada

This page shows the latest US and Canada news and features for those working in and with pharma, biotech and healthcare.

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

Leo Pharma to market AstraZeneca’s brodalumab outside Europe

However, Bausch Health still retains the rights to develop and market brodalumab within the US and Canada. ... The treatment also received approval in the US for the same indication at the same time, where it is marketed as Siliq.

Latest news

  • ‘Missing protein’ biotech Stoke raises $142m in IPO ‘Missing protein’ biotech Stoke raises $142m in IPO

    Continues pioneering research. Stoke Therapeutics has listed on the Nasdaq in the US, raising $142m to advance its pipeline of drugs that aim to restore missing protein expression in genetic diseases. ... treat the disorder, which affects roughly 35, 000

  • ‘Missing protein’ biotech Stoke raises $142m in IPO

    Continues pioneering research. Stoke Therapeutics has listed on the Nasdaq in the US, raising $142m to advance its pipeline of drugs that aim to restore missing protein expression in genetic diseases. ... treat the disorder, which affects roughly 35, 000

  • Roche/GE’s digital medicine alliance bears first fruit Roche/GE’s digital medicine alliance bears first fruit

    Roche. For now, the dashboard is only available in the US and Canada. ... Thrive has just raised $110m in a Series A financing that will help it develop CancerSEEK, a liquid biopsy test developed at Johns Hopkins University in the US and currently being

  • Sobi shows strong growth despite haemophilia competition Sobi shows strong growth despite haemophilia competition

    countries. Marketing rights to the drugs in the US, Canada and Japan are held by Bioverativ, which was acquired last year by Sanofi. ... The ultra-rare disease therapy was licensed from Novimmune for $452m last year, and gives Sobi an expanded presence

  • The Final Frontier The Final Frontier

    But let’s talk about gabapentin. In Canada and the US, gabapentin is indicated as an adjunctive therapy for patients with epilepsy, who are not adequately controlled with conventional therapy. ... But what I do know is that the legalisation of medical

More from news
Approximately 0 fully matching, plus 245 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    US. US and Canada only. # US and EU. Roche’s collaboration with Ionis Pharmaceuticals has a headline of $760m, $1m more than the Tusk deal. ... milestones and royalties, and US profits or losses will be split 50:50.

  • Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

    She is Alnylam’s senior vice president, Europe and Canada and is based at the firm’s European headquarters in Zug, Switzerland. ... In the US and Canada, the company has launched Alynlam Act, a free of charge genetic testing and counselling service.

  • Deal Watch February 2017 Deal Watch February 2017

    In addition to the upfront and milestone payments, Immunomedics will receive tiered double digit royalties on global net sales, retains an option to co-promote IMMU-132 in the US and ... First approved in North America in 1989, Zoladex sales in 2016 were

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Compounding this was the current political uncertainty following regime change in the US and Brexit, with the latter appearing to encourage caution in deal-making which may well continue into 2017. ... This has provided an opportunity for companies

  • Deal Watch October 2016 Deal Watch October 2016

    $4, 300 royalty. Buyout of collaboration. Respiratory 2015. Actavis US and Canada. ... The biosimilar market is heating up. This month Teva has entered into a US and Canada commercialisation arrangement with South Korea's Celltrion.

More from intelligence
Approximately 0 fully matching, plus 35 partially matching documents found.

Latest appointments

  • NDA bolsters its senior team NDA bolsters its senior team

    US, Europe, Canada and other markets. ... Her contributions will help propel client strategy and accelerate programmes across the EU and US, as well as result in new intriguing service offerings that enable innovative companies to navigate the

  • Celgene’s president and COO to retire Celgene’s president and COO to retire

    Smith has over 30 years of business strategy experience across a range of therapeutic areas, having previously held senior leadership roles at Biovail in Canada, France, the US and Hong Kong, ... Smith's successor, Curran, joined Celgene in 2013 as the

  • Bayer appoints president of Americas pharma business Bayer appoints president of Americas pharma business

    Dr Carsten Brunn to lead operations across the US, Canada, Central and Latin America. ... Bayer has appointed Dr Carsten Brunn as the president of its pharmaceuticals business in the Americas, overseeing the company's operations in the US, Canada and

  • Vikas Sinha joins Verona as non-executive director Vikas Sinha joins Verona as non-executive director

    Brings strong US and financial experience to the UK drug development firm. ... Prior to that he spent 11 years at Bayer, holding roles in the US, Canada, Japan and Germany, latterly as chief financial officer for Bayer Pharmaceuticals Corporation in the

  • Merck appoints new North America and China biopharma leaders Merck appoints new North America and China biopharma leaders

    He will be responsible for the Massachusetts-based biopharma business' strategic direction and growth across the US and Canada. . ... chief commercial officer for the US.

More from appointments
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 11 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics